Catalyst Pharmaceutical
CPRX
CPRX was delisted on the 14th of July, 2026.
86 hedge funds and large institutions have $94.3M invested in Catalyst Pharmaceutical in 2018 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 31 increasing their positions, 22 reducing their positions, and 24 closing their positions.
41% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 22
1.92% less ownership
Funds ownership: 49.75% → 47.83% (-1.9%)
11% less funds holding
Funds holding: 97 → 86 (-11)
46% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 24
51% less capital invested
Capital invested by funds: $193M → $94.3M (-$98.6M)
72% less call options, than puts
Call options by funds: $32K | Put options by funds: $113K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$9.61M |
| 2 |
Morgan Stanley
New York
|
+$4.3M |
| 3 |
BC
Broadfin Capital
New York
|
+$3.24M |
| 4 |
BlackRock
New York
|
+$2.06M |
| 5 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$1.98M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$17M |
| 2 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$5.86M |
| 3 |
O
OrbiMed
New York
|
-$4.17M |
| 4 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$3.94M |
| 5 |
JC
JBF Capital
Aspen,
Colorado
|
-$1.92M |
CPRX Hedge Fund Activity: Q4 2018 in Review
86 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q4 2018, worth a combined $94.3M — down 51% from $193M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of CPRX and 13 opened new positions — a net loss of 11 holders — while 22 trimmed existing stakes and 31 added.
The largest buyer was Consonance Capital Management, adding an estimated $9.61M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $17M sold.
- 86 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q4 2018, down from 97 in Q3 2018.
- Funds reported $94.3M of Catalyst Pharmaceutical stock for Q4 2018, down 51% quarter-over-quarter.
- 13 funds opened new Catalyst Pharmaceutical positions in Q4 2018 and 24 closed out, a net change of -11 holders.
- The largest Catalyst Pharmaceutical buyer in Q4 2018 was Consonance Capital Management, an estimated $9.61M added.
- The largest Catalyst Pharmaceutical seller in Q4 2018 was Avoro Capital Advisors, an estimated $17M sold.
Based on aggregated 13F filings for Q4 2018.